1. ArvinAM, FastP, MyersM, PlotkinS, RabinovichR (2004) Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 39: 233–239.
2. BaryawnoN, RahbarA, Wolmer-SolbergN, TaherC, OdebergJ, et al. (2011) Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. The Journal of clinical investigation 121: 4043–4055.
3. MitchellDA, XieW, SchmittlingR, LearnC, FriedmanA, et al. (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncology 10: 10–18.
4. HellstrandK, MartnerA, BergstromT (2013) Valganciclovir in patients with glioblastoma. The New England journal of medicine 369: 2066.
5. PiererM, RotheK, QuandtD, SchulzA, RossolM, et al. (2012) Association of anticytomegalovirus seropositivity with more severe joint destruction and more frequent joint surgery in rheumatoid arthritis. Arthritis and rheumatism 64: 1740–1749.
6. Grahame-ClarkeC, ChanNN, AndrewD, RidgwayGL, BetteridgeDJ, et al. (2003) Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation 108: 678–683.
7. KimS, LeeS, ShinJ, KimY, EvnouchidouI, et al. (2011) Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nature immunology 12: 984–991.
8. JonesTR, SunL (1997) Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. Journal of virology 71: 2970–2979.
9. JonesTR, WiertzEJ, SunL, FishKN, NelsonJA, et al. (1996) Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proceedings of the National Academy of Sciences of the United States of America 93: 11327–11333.
10. JonesTR, HansonLK, SunL, SlaterJS, StenbergRM, et al. (1995) Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. Journal of virology 69: 4830–4841.
11. AhnK, GruhlerA, GalochaB, JonesTR, WiertzEJ, et al. (1997) The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6: 613–621.
12. AhnK, AnguloA, GhazalP, PetersonPA, YangY, et al. (1996) Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proceedings of the National Academy of Sciences of the United States of America 93: 10990–10995.
13. LehnerPJ, KarttunenJT, WilkinsonGW, CresswellP (1997) The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proceedings of the National Academy of Sciences of the United States of America 94: 6904–6909.
14. ParkB, SpoonerE, HouserBL, StromingerJL, PloeghHL (2010) The HCMV membrane glycoprotein US10 selectively targets HLA-G for degradation. The Journal of experimental medicine 207: 2033–2041.
15. GabaevI, SteinbruckL, PokoyskiC, PichA, StantonRJ, et al. (2011) The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cells. PLoS pathogens 7: e1002432.
16. SmithW, TomasecP, AichelerR, LoewendorfA, NemcovicovaI, et al. (2013) Human Cytomegalovirus Glycoprotein UL141 Targets the TRAIL Death Receptors to Thwart Host Innate Antiviral Defenses. Cell host & microbe 13: 324–335.
17. MillerDM, ZhangY, RahillBM, WaldmanWJ, SedmakDD (1999) Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. Journal of immunology 162: 6107–6113.
18. BrowneEP, ShenkT (2003) Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proceedings of the National Academy of Sciences of the United States of America 100: 11439–11444.
19. AbateDA, WatanabeS, MocarskiES (2004) Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. Journal of virology 78: 10995–11006.
20. EngelP, Perez-CarmonaN, AlbaMM, RobertsonK, GhazalP, et al. (2011) Human cytomegalovirus UL7, a homologue of the SLAM-family receptor CD229, impairs cytokine production. Immunology and cell biology 89: 753–766.
21. ChangWL, BaumgarthN, YuD, BarryPA (2004) Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. Journal of virology 78: 8720–8731.
22. PenfoldME, DairaghiDJ, DukeGM, SaederupN, MocarskiES, et al. (1999) Cytomegalovirus encodes a potent alpha chemokine. Proceedings of the National Academy of Sciences of the United States of America 96: 9839–9844.
23. AdamSG, CarauxA, Fodil-CornuN, Loredo-OstiJC, Lesjean-PottierS, et al. (2006) Cmv4, a new locus linked to the NK cell gene complex, controls innate resistance to cytomegalovirus in wild-derived mice. Journal of immunology 176: 5478–5485.
24. KuijpersTW, BaarsPA, DantinC, van den BurgM, van LierRA, et al. (2008) Human NK cells can control CMV infection in the absence of T cells. Blood 112: 914–915.
25. BironCA, ByronKS, SullivanJL (1989) Severe herpesvirus infections in an adolescent without natural killer cells. The New England journal of medicine 320: 1731–1735.
26. GazitR, GartyBZ, MonseliseY, HofferV, FinkelsteinY, et al. (2004) Expression of KIR2DL1 on the entire NK cell population: a possible novel immunodeficiency syndrome. Blood 103: 1965–1966.
27. SternM, HadayaK, HongerG, MartinPY, SteigerJ, et al. (2011) Telomeric rather than centromeric activating KIR genes protect from cytomegalovirus infection after kidney transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 11: 1302–1307.
28. Stern-GinossarN, ElefantN, ZimmermannA, WolfDG, SalehN, et al. (2007) Host immune system gene targeting by a viral miRNA. Science 317: 376–381.
29. TomasecP, BraudVM, RickardsC, PowellMB, McSharryBP, et al. (2000) Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287: 1031.
30. WangEC, McSharryB, RetiereC, TomasecP, WilliamsS, et al. (2002) UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proceedings of the National Academy of Sciences of the United States of America 99: 7570–7575.
31. WillsMR, AshiruO, ReevesMB, OkechaG, TrowsdaleJ, et al. (2005) Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. Journal of immunology 175: 7457–7465.
32. BennettNJ, AshiruO, MorganFJ, PangY, OkechaG, et al. (2010) Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. Journal of immunology 185: 1093–1102.
33. CosmanD, MullbergJ, SutherlandCL, ChinW, ArmitageR, et al. (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123–133.
34. SutherlandCL, ChalupnyNJ, SchooleyK, VandenBosT, KubinM, et al. (2002) UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. Journal of immunology 168: 671–679.
35. WuJ, ChalupnyNJ, ManleyTJ, RiddellSR, CosmanD, et al. (2003) Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. Journal of immunology 170: 4196–4200.
36. KubinM, CassianoL, ChalupnyJ, ChinW, CosmanD, et al. (2001) ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. European journal of immunology 31: 1428–1437.
37. LeongCC, ChapmanTL, BjorkmanPJ, FormankovaD, MocarskiES, et al. (1998) Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. The Journal of experimental medicine 187: 1681–1687.
38. GriffinC, WangEC, McSharryBP, RickardsC, BrowneH, et al. (2005) Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18. The Journal of general virology 86: 2999–3008.
39. Prod'hommeV, GriffinC, AichelerRJ, WangEC, McSharryBP, et al. (2007) The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1− NK cells. Journal of immunology 178: 4473–4481.
40. TomasecP, WangEC, DavisonAJ, VojtesekB, ArmstrongM, et al. (2005) Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nature immunology 6: 181–188.
41. VivierE, TomaselloE, BaratinM, WalzerT, UgoliniS (2008) Functions of natural killer cells. Nature immunology 9: 503–510.
42. EagleRA, TrowsdaleJ (2007) Promiscuity and the single receptor: NKG2D. Nature reviews Immunology 7: 737–744.
43. EagleRA, TraherneJA, HairJR, JafferjiI, TrowsdaleJ (2009) ULBP6/RAET1L is an additional human NKG2D ligand. European journal of immunology 39: 3207–3216.
44. EagleRA, TraherneJA, AshiruO, WillsMR, TrowsdaleJ (2006) Regulation of NKG2D ligand gene expression. Human immunology 67: 159–169.
45. VenkataramanGM, SuciuD, GrohV, BossJM, SpiesT (2007) Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. Journal of immunology 178: 961–969.
46. RolleA, Mousavi-JaziM, ErikssonM, OdebergJ, Soderberg-NauclerC, et al. (2003) Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. Journal of immunology 171: 902–908.
47. AshiruO, BennettNJ, BoyleLH, ThomasM, TrowsdaleJ, et al. (2009) NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. Journal of virology 83: 12345–12354.
48. ChalupnyNJ, Rein-WestonA, DoschS, CosmanD (2006) Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochemical and biophysical research communications 346: 175–181.
49. CheeMS, BankierAT, BeckS, BohniR, BrownCM, et al. (1990) Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Current topics in microbiology and immunology 154: 125–169.
50. RauletDH, GasserS, GowenBG, DengW, JungH (2013) Regulation of ligands for the NKG2D activating receptor. Annual review of immunology 31: 413–441.
51. DolanA, CunninghamC, HectorRD, Hassan-WalkerAF, LeeL, et al. (2004) Genetic content of wild-type human cytomegalovirus. The Journal of general virology 85: 1301–1312.
52. GathererD, SeirafianS, CunninghamC, HoltonM, DarganDJ, et al. (2011) High-resolution human cytomegalovirus transcriptome. Proceedings of the National Academy of Sciences of the United States of America 108: 19755–19760.
53. DunnW, ChouC, LiH, HaiR, PattersonD, et al. (2003) Functional profiling of a human cytomegalovirus genome. Proceedings of the National Academy of Sciences of the United States of America 100: 14223–14228.
54. McSharryBP, BurgertHG, OwenDP, StantonRJ, Prod'hommeV, et al. (2008) Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. Journal of virology 82: 4585–4594.
55. TavalaiN, StammingerT (2011) Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus research 157: 128–133.
56. ZouY, BresnahanW, TaylorRT, StastnyP (2005) Effect of human cytomegalovirus on expression of MHC class I-related chains A. Journal of immunology 174: 3098–3104.
57. DasS, PellettPE (2007) Members of the HCMV US12 family of predicted heptaspanning membrane proteins have unique intracellular distributions, including association with the cytoplasmic virion assembly complex. Virology 361: 263–273.
58. DasS, Skomorovska-ProkvolitY, WangFZ, PellettPE (2006) Infection-dependent nuclear localization of US17, a member of the US12 family of human cytomegalovirus-encoded seven-transmembrane proteins. Journal of virology 80: 1191–1203.
59. LesniewskiM, DasS, Skomorovska-ProkvolitY, WangFZ, PellettPE (2006) Primate cytomegalovirus US12 gene family: a distinct and diverse clade of seven-transmembrane proteins. Virology 354: 286–298.
60. HenkeN, LisakDA, SchneiderL, HabichtJ, PergandeM, et al. (2011) The ancient cell death suppressor BAX inhibitor-1. Cell calcium 50: 251–260.
61. YamajiT, NishikawaK, HanadaK (2010) Transmembrane BAX inhibitor motif containing (TMBIM) family proteins perturbs a trans-Golgi network enzyme, Gb3 synthase, and reduces Gb3 biosynthesis. The Journal of biological chemistry 285: 35505–35518.
62. LeeGH, KimHR, ChaeHJ (2012) Bax inhibitor-1 regulates the expression of P450 2E1 through enhanced lysosome activity. The international journal of biochemistry & cell biology 44: 600–611.
63. GubserC, BergamaschiD, HollinsheadM, LuX, van KuppeveldFJ, et al. (2007) A new inhibitor of apoptosis from vaccinia virus and eukaryotes. PLoS pathogens 3: e17.
64. WestonK, BarrellBG (1986) Sequence of the short unique region, short repeats, and part of the long repeats of human cytomegalovirus. Journal of molecular biology 192: 177–208.
65. EldeNC, ChildSJ, EickbushMT, KitzmanJO, RogersKS, et al. (2012) Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. Cell 150: 831–841.
66. DavisonAJ, DolanA, AkterP, AddisonC, DarganDJ, et al. (2003) The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. The Journal of general virology 84: 17–28.
67. MarshAK, WillerDO, AmbagalaAP, DzambaM, ChanJK, et al. (2011) Genomic sequencing and characterization of cynomolgus macaque cytomegalovirus. Journal of virology 85: 12995–13009.
68. HansenSG, StrelowLI, FranchiDC, AndersDG, WongSW (2003) Complete sequence and genomic analysis of rhesus cytomegalovirus. Journal of virology 77: 6620–6636.
69. Davison AJ, Holton M, Dolan A, Dargan DJ, Gatherer D, et al.. (2013) Comparitive genomics of primate cytomegaloviruses. In: Reddehase MJ, editor. Cytomegaloviruses: from Molecular Pathogenesis to Intervention. Norwich, UK: Caister Academic Press.
70. GuoYW, HuangES (1993) Characterization of a structurally tricistronic gene of human cytomegalovirus composed of U(s)18, U(s)19, and U(s)20. Journal of virology 67: 2043–2054.
71. Towler JC (2007) Transcriptome activity of human cytomeglovirus (strain Merlin) in fibroblasts, epithelial cells and astrocytes. United Kingdom: University of Glasgow Press. 228 p.
72. TowlerJC, EbrahimiB, LaneB, DavisonAJ, DarganDJ (2012) Human cytomegalovirus transcriptome activity differs during replication in human fibroblast, epithelial and astrocyte cell lines. The Journal of general virology 93: 1046–1058.
73. FurmanMH, DeyN, TortorellaD, PloeghHL (2002) The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. Journal of virology 76: 11753–11756.
74. WiertzEJ, JonesTR, SunL, BogyoM, GeuzeHJ, et al. (1996) The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84: 769–779.
75. McSharryBP, JonesCJ, SkinnerJW, KiplingD, WilkinsonGW (2001) Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus. The Journal of general virology 82: 855–863.
76. McCannFE, EissmannP, OnfeltB, LeungR, DavisDM (2007) The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. Journal of immunology 178: 3418–3426.
77. StantonRJ, BaluchovaK, DarganDJ, CunninghamC, SheehyO, et al. (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. The Journal of clinical investigation 120: 3191–3208.
78. OramJD, DowningRG, AkriggA, DolleryAA, DugglebyCJ, et al. (1982) Use of recombinant plasmids to investigate the structure of the human cytomegalovirus genome. The Journal of general virology 59: 111–129.
79. BradleyAJ, LurainNS, GhazalP, TrivediU, CunninghamC, et al. (2009) High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. The Journal of general virology 90: 2375–2380.
80. StantonRJ, McSharryBP, ArmstrongM, TomasecP, WilkinsonGW (2008) Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. BioTechniques 45: 659–662, 664–658.
81. Prod'hommeV, SugrueDM, StantonRJ, NomotoA, DaviesJ, et al. (2010) Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. The Journal of general virology 91: 2034–2039.